Physician profile
Chen Xu
NPI 1821418641
$14,999.90
in general payments reported to CMS, 2019-2025
19 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $222 · 2021: $1,785 · 2022: $2,459 · 2023: $1,897 · 2024: $7,141 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Consulting Fee: $4,000 · Travel and Lodging: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.33 |
| Consulting Fee | $4,000.00 |
| Travel and Lodging | $1,918.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Retropsoas Technologies, LLC | $4,000.00 | 2024 | |
| Stryker Corporation | $3,810.57 | 2021-2025 | Everest Spinal System, Aero-Ll, N/A |
| Abbott Laboratories | $3,158.79 | 2019-2025 | Penta, Eterna, Proclaim |
| Si-Bone, INC. | $736.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $659.81 | 2019-2024 | Tezspire |
| Medtronic, INC. | $583.29 | 2022-2025 | Cd Horizon Spinal System, Infinity Occipitocervical Upper Thoracic System, O-Arm |
| Smith+Nephew, INC. | $326.91 | 2022-2024 | Pico, Pico 7 |
| Globus Medical, INC. | $267.35 | 2024 | Excelsius Deformity, Altera |
| Aesculap, INC. | $263.24 | 2023 | Progav 2.0 |
| Cerapedics INC. | $214.20 | 2023-2025 | I-Factor Peptide Enhanced Bone Graft |
| Depuy Synthes Sales INC. | $193.44 | 2021 | |
| Alphatec Spine, INC | $173.85 | 2021 | |
| Kuros Biosciences USA, INC | $172.86 | 2023 | |
| Baxter Healthcare | $171.70 | 2023 | Floseal, Tisseel, Biosurgery - Floseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.78 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87.27 | 2022 | |
| Innovation Technologies INC | $34.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.80 | 2024 | Caplyta |
| Integra Lifesciences Corporation | $20.02 | 2025 | Codman Certas, Codman Hakim, Cusa Clarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.